Clover Health Investments, Corp. - Class A Common stock (CLOV)
2.5850
-0.0150 (-0.58%)
NASDAQ · Last Trade: Nov 11th, 12:42 PM EST
Detailed Quote
Previous Close
2.600
Open
2.600
Bid
2.580
Ask
2.590
Day's Range
2.520 - 2.630
52 Week Range
2.120 - 4.870
Volume
1,968,304
Market Cap
230.60M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
11,510,835
Chart
About Clover Health Investments, Corp. - Class A Common stock (CLOV)
Clover Health Investments Corp is a healthcare technology company focused on improving the health outcomes of Medicare beneficiaries. By utilizing its proprietary data-driven platform, Clover Health aims to enhance care delivery and streamline operations for its members, promoting preventive care and tailored health services. The company partners with healthcare providers to deliver more efficient and personalized care, ultimately seeking to reduce costs and improve patient satisfaction in the healthcare system. Through innovation and technology, Clover Health strives to make healthcare more accessible and effective for seniors across the United States. Read More
Clover Health’s third quarter was marked by robust revenue growth, yet a negative market reaction reflected investor concerns around profitability and cost trends. Management attributed the strong top-line performance to accelerated membership gains, especially as competitors retrenched. However, CEO Andrew Toy acknowledged that the company "missed our targets on both overall adjusted EBITDA and stars," citing higher-than-expected utilization and challenges managing a surge of new members, which diluted near-term margins and pressured overall results.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how health insurance providers stocks fared in Q3, starting with Clover Health (NASDAQ:CLOV).
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 8.4% in the morning session after the stock's negative momentum continued as the company reported disappointing third-quarter 2025 financial results and cut its full-year profitability forecast.
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 24.2% in the morning session after the company reported disappointing third-quarter financial results and cut its full-year profitability forecast. While the Medicare-focused company saw its revenue climb by 50.1% compared to the previous year, its earnings per share missed forecasts. Looking ahead, Clover Health lowered its full-year guidance for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to a midpoint of $22.5 million, which was significantly below analysts' expectations and implied a reduction from previous forecasts. The company attributed the weaker outlook to higher-than-expected medical costs and increased healthcare usage trends among its members. This guidance overshadowed its revenue, which beat Wall Street's estimates, as investors focused on the pressure on future profitability.
Health insurance company Clover Health (NASDAQ:CLOV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 50.1% year on year to $496.7 million. Its GAAP loss of $0.05 per share was $0.02 below analysts’ consensus estimates.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Health insurance company Clover Health (NASDAQ:CLOV) announced better-than-expected revenue in Q3 CY2025, with sales up 50.1% year on year to $496.7 million. Its GAAP loss of $0.05 per share was $0.02 below analysts’ consensus estimates.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership and resilience. While the overall market sentiment exuded robust optimism, the healthcare sector itself showcased a
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Over the past six months, Clover Health’s shares (currently trading at $2.63) have posted a disappointing 18.1% loss, well below the S&P 500’s 32.7% gain. This may have investors wondering how to approach the situation.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
